Abstract
Caffeine is a first-line option for the neonatal intensive care management of apnea of prematurity (AOP) in preterm infants. This is the first study in the literature to evaluate the cost effectiveness of the off-label high dose (HD) of caffeine versus the approved standard lower dose (LD) of caffeine for the treatment of AOP in neonates.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
